A novel aromatase inhibitor, vorozole, shows antitumor activity and a decrease of tissue insulin-like growth factor-I level in 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors

Authors
Sugamata, N Koibuchi, Y Iino, Y Morishita, Y
Citation
N. Sugamata et al., A novel aromatase inhibitor, vorozole, shows antitumor activity and a decrease of tissue insulin-like growth factor-I level in 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors, INT J ONCOL, 14(2), 1999, pp. 259-263
Citations number
45
Categorie Soggetti
Onconogenesis & Cancer Research
Journal title
INTERNATIONAL JOURNAL OF ONCOLOGY
ISSN journal
10196439 → ACNP
Volume
14
Issue
2
Year of publication
1999
Pages
259 - 263
Database
ISI
SICI code
1019-6439(199902)14:2<259:ANAIVS>2.0.ZU;2-3
Abstract
Effects of vorozole, a potent and specific nonsteroidal aromatase inhibitor , were evaluated on female Sprague-Dawley (SD) rats with 7,12-dimethylbenz[ a] anthracene (DMBA)-induced mammary tumors. Vorozole at a dose of 0.25, 1. 0 and 4.0 mg/kg was orally administered once a day for 28 consecutive days. A significant regression in tumor size was observed in each treated group at 1, 2, 3 and 4 weeks after the start of treatment compared with control g roup. Tissue insulin-like growth factor I (IGF-I) in the DMBA-induced tumor s in each treated group significantly decreased in a dose-dependent fashion compared with control group. These results show the mechanism of vorozole in DMBA-induced rat mammary tumors.